BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 26602092)

  • 1. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
    Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
    Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.
    Krabbe LM; Svatek RS; Shariat SF; Messing E; Lotan Y
    Urol Oncol; 2015 Feb; 33(2):65.e19-25. PubMed ID: 25044253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LINE1 methylation levels in pre-diagnostic leukocyte DNA and future renal cell carcinoma risk.
    Karami S; Andreotti G; Liao LM; Pfeiffer RM; Weinstein SJ; Purdue MP; Hofmann JN; Albanes D; Mannisto S; Moore LE
    Epigenetics; 2015; 10(4):282-92. PubMed ID: 25647181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial.
    Gelfond J; Al-Bayati O; Kabra A; Iffrig K; Kaushik D; Liss MA
    Urol Oncol; 2018 Jul; 36(7):340.e1-340.e6. PubMed ID: 29779672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
    Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
    PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep Learning to Assess Long-term Mortality From Chest Radiographs.
    Lu MT; Ivanov A; Mayrhofer T; Hosny A; Aerts HJWL; Hoffmann U
    JAMA Netw Open; 2019 Jul; 2(7):e197416. PubMed ID: 31322692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection criteria for lung-cancer screening.
    Tammemägi MC; Katki HA; Hocking WG; Church TR; Caporaso N; Kvale PA; Chaturvedi AK; Silvestri GA; Riley TL; Commins J; Berg CD
    N Engl J Med; 2013 Feb; 368(8):728-36. PubMed ID: 23425165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
    Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
    Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.
    Tammemagi CM; Pinsky PF; Caporaso NE; Kvale PA; Hocking WG; Church TR; Riley TL; Commins J; Oken MM; Berg CD; Prorok PC
    J Natl Cancer Inst; 2011 Jul; 103(13):1058-68. PubMed ID: 21606442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D binding protein and risk of renal cell carcinoma in the prostate, lung, colorectal and ovarian cancer screening trial.
    Kratzer TB; Weinstein SJ; Albanes D; Mondul AM
    Int J Cancer; 2020 Aug; 147(3):669-674. PubMed ID: 31659740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Pinsky PF; Miller A; Kramer BS; Church T; Reding D; Prorok P; Gelmann E; Schoen RE; Buys S; Hayes RB; Berg CD
    Am J Epidemiol; 2007 Apr; 165(8):874-81. PubMed ID: 17244633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.
    O'Grady TJ; Kitahara CM; DiRienzo AG; Boscoe FP; Gates MA
    PLoS One; 2014; 9(9):e106880. PubMed ID: 25192282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analgesic use and risk of renal cell carcinoma: A case-control, cohort and meta-analytic assessment.
    Karami S; Daughtery SE; Schwartz K; Davis FG; Ruterbusch JJ; Wacholder S; Graubard BI; Berndt SI; Hofmann JN; Purdue MP; Moore LE; Colt JS
    Int J Cancer; 2016 Aug; 139(3):584-92. PubMed ID: 27009534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants.
    Mir MC; Stephenson AJ; Grubb RL; Black A; Kibel AS; Izmirlian G
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2241-9. PubMed ID: 24089460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
    Pierre-Victor D; Pinsky PF
    JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The National Lung Screening Trial Premise of Null and Chest Radiography Equivalence Is Open to Question.
    Reich JM; Kim JS
    AJR Am J Roentgenol; 2015 Aug; 205(2):278-9. PubMed ID: 26204275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.